Clostridioides difficile (C. difficile) is a gram-positive, anaerobic spore-forming bacterium and a major cause of antibiotic-associated diarrhea. Humans are naturally resistant to C. difficile infection (CDI) owing to the protection provided by healthy gut microbiota. When the …

Clinical trial success for two proprietary bacteria mixtures

Ridinilazole was tested in a Phase 3 trial in the treatment of C. Difficile.

Clostridioides difficile is an enteric bacterium whose exotoxins, TcdA and TcdB, inactivate small GTPases within the host cells, leading to bloody diarrhea. In prior work, our group engineered a panel of potent TcdB-neutralizing designed ankyrin repeat proteins (DARPin) as oral therapeutics against …

The Asia-Pacific region has seen a 158% increase in the number of musculoskeletal disorders trials taking place over the past...Read More...

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

The investigational therapy, ibezapolstat, demonstrated promising results in early trials.

Researchers at Albert Einstein College of Medicine, led by Vern Schramm, Ph.D., have developed a novel compound that targets C. difficile.

The intestinal pathogen Clostridioides (C.) difficile is a major cause of diarrhea both in hospitals and outpatient in industrialized countries. This bacterium produces two large exotoxins, toxin A (TcdA) and toxin B (TcdB), which are directly responsible for the onset of clinical symptoms of …

Proline racemases (PRAC), catalyzing the L-proline and D-proline interconversion, are essential factors in eucaryotic pathogenes such as Trypanosoma cruzi, Trypanosoma vivax and Clostridioides difficile. If the discovery of irreversible inhibitors of Trypanosoma cruzi PRAC (TcPRAC) led to innovative …

Scientists around the world have been working in earnest to improve understanding of an increasingly virulent superbug, Clostridium difficile. The highly contagious hospital-acquired pathogen, designated by the Centers for Disease Control and Prevention as one of the five most urgent threats to the U.S. healthcare system, causes more than 500,000 infections and 29,000 deaths each year at a total societal cost exceeding $5 billion.

Many of the measures put in place because of COVID-19 have also helped to reduce the rates of C difficile infections.

Vedanta revealed positive new data for its C. difficile microbiome therapeutic. But is it too late an entrant into the field?

Acurx Pharmaceuticals, Inc. announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.

The investigational therapy, ibezapolstat, demonstrated promising results in early trials.

Clostridioides difficile is one of the major causes of nosocomial infections worldwide. Antibiotic-associated diarrhea, pseudomembranous colitis, and toxic megacolon are the most common forms of C. difficile infection (CDI). Considering the high antibiotic resistance of C. difficile isolates and the …

Clostridioides difficile infection (CDI) is a leading cause of antibiotic-associated diarrhoea. Adhesion of this Gram-positive pathogen to the intestinal epithelium is a crucial step in CDI, with recurrence and relapse of disease dependent on epithelial interaction of its endospores. Close pr …

.@Summitplc’s #ridinilazole reduced recurrence of #Cdiff #infections but did not reach superiority to #vancomycin in Ph3 #ClinicalTrialsBelieve precision #antibiotic spares #microbiome from damagehttps://t.co/ED6zpkmEqQ#Cdifficile #InfectiousDiseases pic.twitter.com/oUc6TuNkn7— DDNews Online (@DDNewsOnline) December 20, 2021

Recursion Pharma (RXRX) is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities.

Bacterial adhesion is the first stage of colonisation and biofilm formation by C. difficile. Cell wall proteins (Cwp) 84 and 66 play crucial roles in the pathophysiology of C. difficile and may affect bacterial adhesion. Sialylated human milk oligosaccharides (HMOs) have potential to inhibit bacteri …

Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutrali …

Infectious Disease Society of America and Society for Healthcare Epidemiology of America make 3 new treatment recommendations for adults.

Seres Therapeutics, Inc. today announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Lumen also announces successful Cohort 1 results in Phase 1 clinical trial.

Chemical engineers created a coating for microbes that could make it easier to deploy the organisms to treat gastrointestinal diseases. The human gut is home to thousands of species of bacteria, and some of those bacteria have the potential to treat a variety of gastrointestinal diseases. Some sp

Dr. Carl V. Crawford led a panel in discussing treatments in the pipeline for CDI.